Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0TS8E
|
|||
| Former ID |
DNCL003146
|
|||
| Drug Name |
ADX71149
|
|||
| Indication | Epilepsy [ICD-11: 8A60-8A68] | Phase 1 | [1] | |
| Anxiety disorder [ICD-11: 6B00-6B0Z; ICD-10: R45.0] | Discontinued in Phase 2 | [2] | ||
| Psychiatric disorder [ICD-11: 6E8Z] | Discontinued in Phase 2 | [3] | ||
| Company |
Addex Pharmaceuticals; Johnson & Johnson Pharmaceutical
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H25ClN2O
|
|||
| Canonical SMILES |
CCCCN1C=CC(=C(C1=O)Cl)N2CCC(CC2)C3=CC=CC=C3
|
|||
| InChI |
1S/C20H25ClN2O/c1-2-3-12-23-15-11-18(19(21)20(23)24)22-13-9-17(10-14-22)16-7-5-4-6-8-16/h4-8,11,15,17H,2-3,9-10,12-14H2,1H3
|
|||
| InChIKey |
HYOGJHCDLQSAHX-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1127498-03-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Metabotropic glutamate receptor 2 (mGluR2) | Target Info | Modulator | [4] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Glutamatergic synapse | ||||
| Cocaine addiction | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Ionotropic glutamate receptor pathway | ||||
| Metabotropic glutamate receptor group II pathway | ||||
| Reactome | G alpha (i) signalling events | |||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
| WikiPathways | GPCRs, Class C Metabotropic glutamate, pheromone | |||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT01323205) Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia. U.S. National Institutes of Health. | |||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030424) | |||
| REF 4 | MGlu2 receptor-mediated modulation of conditioned avoidance behavior in rats. European journal of pharmacology. 01/2014; 727(1). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.